Last €35.33 EUR
Change Today +0.03 / 0.08%
Volume 121.2K
DIA On Other Exchanges
Symbol
Exchange
BrsaItaliana
Stuttgart
OTC US
OTC US
As of 11:30 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

diasorin spa (DIA) Snapshot

Open
€35.20
Previous Close
€35.30
Day High
€35.56
Day Low
€35.09
52 Week High
01/30/15 - €35.56
52 Week Low
08/8/14 - €26.00
Market Cap
2.0B
Average Volume 10 Days
70.7K
EPS TTM
€1.54
Shares Outstanding
55.9M
EX-Date
05/19/14
P/E TM
22.9x
Dividend
€0.55
Dividend Yield
1.56%
Current Stock Chart for DIASORIN SPA (DIA)

Related News

No related news articles were found.

diasorin spa (DIA) Related Businessweek News

No Related Businessweek News Found

diasorin spa (DIA) Details

DiaSorin S.p.A. is engaged in the development, production, and commercialization of diagnostic tests that are designed for hospital and private testing laboratories for use in different clinical areas in the market of immunodiagnostics and molecular diagnostics. The company offers immunodiagnostics products for diagnosis of infectious diseases; immunoassays for the management of bone and calcium metabolic related diseases; endocrinology products for endocrine system diseases; such as diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology, bone and calcium metabolic related diseases, hypertension, and oncology; enzyme linked immunosorbent assays; and SPQ serum protein quantification assays. Its immunodiagnostics instruments include LIAISON XL, an automated chemiluminescence analyzer; LIAISON analyzer; ETI Max 3000, an automated microtiter plate analyzer; EVOlyzer 2-150/8 with disposable tips; and ELISA washers and readers. The company also offers molecular diagnostic products, including systems, software, kits, reagents, and consumables, such as Bullet Pro to perform extractions from different biological samples as required in big laboratories; LIAISON IXT to extract the nucleic acid from different biological samples and it is used in combination with LIAISON IAM amplification system; and LIAISON IAM to diagnose and monitor various infectious diseases and Onco-hematology parameters. In addition, it provides Middleware DiaLink 3000, a middleware solution. The company sells its products directly, as well as through an international network of independent distributors in Europe, Africa, Central America, South America, the Asia Pacific, and North America. DiaSorin S.p.A. was founded in 1968 and is headquartered in Saluggia, Italy.

Founded in 1968

diasorin spa (DIA) Top Compensated Officers

Chief Executive Officer, General Manager and ...
Total Annual Compensation: €705.5K
Senior Corporate Vice President of Commercial...
Total Annual Compensation: €435.7K
Compensation as of Fiscal Year 2013.

diasorin spa (DIA) Key Developments

DiaSorin Launches Test for Gastro-Intestinal Tract Inflammatory Diseases

DiaSorin has launched the test for the quantitative determination of Calprotectin in stool samples, available outside the US only. After having completed the panel for Gastro-Intestinal infections, DiaSorin launched the first completely automated test for Gastro-Intestinal tract inflammatory diseases, expanding its CLIA offer on LIAISON platforms in a growing market.

DiaSorin SpA Launches Leukaemia Blood Test

DiaSorin SpA announced that it has launched a molecular diagnostic test to detect the marker for two types of leukaemia. DiaSorin is launching the onco-haematology test for the markets outside the US and the UK to detect the BCR-ABL marker in blood samples to help diagnose suspected Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). The BCR-ABL marker is the genetic cause of 95% of CML and of 30% of ALL.

Diasorin S.P.A. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Confirms Earnings Guidance for the Year 2014

DiaSorin S.p.A. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported sales and service revenues of €109,025,000, EBIT was €32,150,000, profit before taxes was €32,231,000, net profit of €21,311,000 and EBITDA was €40,018,000 against sales and service revenues of €104,202,000, EBIT was €31,715,000, profit before taxes was €30,778,000, net profit of €20,014,000 and EBITDA was €38,628,000 a year ago. Free cash flow of the group was equal to €32.1 million compared to €28.5 million a year ago. For the nine months, the company reported sales and service revenues of €325,796,000, EBIT was €95,538,000, profit before taxes was €95,083,000, net profit of €61,284,000 and EBITDA was €118,095,000 against sales and service revenues of €323,921,000, EBIT was €101,298,000, profit before taxes was €97,492,000, net profit of €61,055,000 and EBITDA was €122,501,000 a year ago. Net cash from operating activities was €39,015,000 compared to €36,706,000 a year ago. Free cash flow was equal to €65.9 million compared to €65.2 million a year ago. Free cash flow of the group was equal to €71.2 million compared to €65.4 million a year ago. In view of the group's operating performance after September 30, 2014 and taking into account possible evolutions of the global macroeconomic scenario and the diagnostic sector in particular, management confirmed the guidance for 2014: Revenues: growth between 3% and 5% at CER compared with 2013. EBITDA: growth equal to 3% at CER compared with 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DIA:IM €35.33 EUR +0.03

DIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $115.06 USD +0.24
Corgenix Medical Corp $0.26 USD 0.00
ERBA Diagnostics Inc $3.62 USD +0.02
Meridian Bioscience Inc $17.50 USD -0.28
Trinity Biotech PLC $18.74 USD -0.05
View Industry Companies
 

Industry Analysis

DIA

Industry Average

Valuation DIA Industry Range
Price/Earnings 20.6x
Price/Sales 3.9x
Price/Book 3.7x
Price/Cash Flow 21.2x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIASORIN SPA, please visit www.diasorin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.